Clinical and Experimental Reproductive Medicine

  • 제30권1호
  • /
  • Pages.23-29
  • /
  • 2003
  • /
  • 2233-8233(pISSN)
  • /
  • 2233-8241(eISSN)
대한생식의학회 (The Korean Society for Reproductive Medicine)
권호 표지

자궁근종 성장에 있어서 내인성 성호르몬의 역할

Urinary Profiles of the Endogenous Steroids in Pre-Menopausal Women with Uterine Leiomyoma

  • 정병화 (한국과학기술 연구원 생체대사 연구센터) ;
  • 배상욱 (연세대학교 의과대학 산부인과학교실) ;
  • 정봉철 (한국과학기술 연구원 생체대사 연구센터) ;
  • 김세광 (연세대학교 의과대학 산부인과학교실) ;
  • 박기현 (연세대학교 의과대학 산부인과학교실)
  • Jung, Byung-Hwa (Bioanalysis and Biotransformation Research Center, Korea Institute of Science and Technology) ;
  • Bai, Sang-Wook (Department of Obstetrics and Gynecology, College of Medicine, Yonsei University) ;
  • Chung, Bong-Chul (Bioanalysis and Biotransformation Research Center, Korea Institute of Science and Technology) ;
  • Kim, Sei-Kwang (Department of Obstetrics and Gynecology, College of Medicine, Yonsei University) ;
  • Park, Ki-Hyun (Department of Obstetrics and Gynecology, College of Medicine, Yonsei University)
  • 발행 : 2003.03.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목 적: 본 연구의 목적은 내인성 성호르몬이 자궁근종의 성장에 미치는 영향을 알아보고자 연구를 시행하였다. 연구대상 및 방법: 폐경전 자궁근종 환자 27명과 같은 연령대의 정상여성 25명을 대상으로 하였다. 모든 대상군의 여성에서 24시간 소변을 모아서 소변내 estrogen, androgen의 대사체들을 GC-MS를 이용하여 측정하였으며 두 군에서의 차이를 비교분석 하였다. 결 과: 소변내 $17{\beta}$-estradiol, 5-androstene-$3{\beta}$, $16{\beta}$, $17{\beta}$-triol, 11-keto-ethiocholanolone, $11{\beta}$-hydroxy-androsterone, THS, THA, THE, a-cortolone, a-cortol 및 $\beta$-cortol가 환자군에서 의의있게 증가하였으며 $17{\beta}$estradiol/estrone 및 $11{\beta}$-hydroxy-ethiocholanolone/$11{\beta}$-hydroxy-androsterone도 환자군에서 의의있게 증가하였다. 결 론: 자궁근종의 성장은 요중 estrogen과 androgen의 농도와 밀접한 관련이 있으며 이는 환자의 스테로이드 호르몬 대사 감소에 기인한 것으로 사료된다.

키워드

참고문헌

  1. Buttram VC JR, Reiter RC. Uterine leiomyomata: etiology, symptomatology and management. Fertil Steril 1981; 36: 433-45 https://doi.org/10.1016/S0015-0282(16)45789-4
  2. Friedman AJ, Lobel SM, Rein MS, Barbieri RL. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropinreleasing hormone agonist: The estrogen threshold hypothesis. Am J Obstet Gynecol 1990; 63: 1114-9
  3. Berek JS, Adashi EY, Hillard RA. Novak's Gynecology 12th rev. ed. Baltimore: Williams & Wilkins. 1996: 149
  4. Andersen J, Barbieri RL. Abnormal gene expression in uterine leiomyomas. J Soc Gynecol Investig 1995;2: 663-72 https://doi.org/10.1016/1071-5576(95)00021-6
  5. Ichibura T, Kawamura N, Ito F, Shibata S, Minakuchi-Minakuchi K, Tsujimura A, Umesaki N, Ogita S. Correlation between the growth of uterine leiomyomata and estrogen and progesterone receptor content in needle biopsy specimens. Fertil Steril 1998; 70: 967-71 https://doi.org/10.1016/S0015-0282(98)00300-8
  6. Sudan O, Ginath S, Sofer D, Rotmensch S, Debby A, Glezerman M, Zakut H. The role of tamoxifen in the treatment of sysptomatic uterine leiomyomata -a pilot study. Eur J Obstet Gynecol Reprod Biol 2001; 96: 183-6 https://doi.org/10.1016/S0301-2115(00)00468-1
  7. Porter KB, Tsibris JCM, Porter G, Fuchs-young R, Nicosia SV, O'Brien WF, pellacy WN. Effect of raloxifene in a guinea pig model for leiomyomas. Gynecology 1998; 179: 1283-7
  8. Friedman AJ, Barbieri RL, Doubliet PM, Fine C, Schiff I. A randomized, double-blind trial of gonadotropin-releasing hormone gonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri. Fertil Steril 1988; 49:404-9 https://doi.org/10.1016/S0015-0282(16)59763-5
  9. Andreyko JL, Blummenfeld Z, Marshall LA, Monroe SE, Hricak H, Jaffé RB. Use of an agonistic analog of gonadotropin-releasing hormone (nafarelin) to treat leiomyomas: assessment by magnetic resonance imaging. Am J Obstet Gynecol 1988;159: 903-10 https://doi.org/10.1016/S0002-9378(88)80167-4
  10. Sudan O, van Iddekinge B, van Gelderen CJ, Savage N, Becker PJ, van der Walt LA, Robinson M. Oestrogen and progesterone receptor concentrations in leiomyoma and normal myometrium. Ann Clin Biochem 1987; 24: 263-7 https://doi.org/10.1177/000456328702400304
  11. Rein MS, Friedman AJ, Stuart JM, MacLaughlin DT. Fibroid and myometrial steroid receptors in women treated with the gonadotropin-releasing hor- mone agonist leuprolide acetate. Fertil Stril 1990; 53:1018-23 https://doi.org/10.1016/S0015-0282(16)53578-X
  12. Brandon DD, Erickson TE, Keenan EJ, Strawn EY, Novy MJ, Burry KA, Warner C, Clinton CM. Estrogenreceptor gene expression in human uterine eiomyomata. J Clin Endocrinol Metab 1995; 80: 1876-81 https://doi.org/10.1210/jc.80.6.1876
  13. Englund K, Blanck A, Gustavasson I, Lundkvist U, Sjoblom P, Norgren A, Nindblom B. Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropinreleasing hormone treatment. J Clin Endocrinol Metab 1998; 83: 4092-6 https://doi.org/10.1210/jc.83.11.4092
  14. Cirkel U, Ochs H, Roehl A, Schneider HPG. Estrogen and progesterone receptor content of enucleated uterine myoma after lutenizing hormone-releasing hormone. Acta Obstet Gynecol Scand 1994; 73: 328-32 https://doi.org/10.3109/00016349409015773
  15. Otubu JA, Buttram VC, Besch NF, Besch PK. Unconjugated steroids in leiomyomas and tumorbearing myometrium. Am J Obstet Gynecol 1982; 143: 130-3 https://doi.org/10.1016/0002-9378(82)90640-8
  16. Potgieter HC, Magagane F, Bester MJ. Oestrogen and progesterone receptor status and PgR/ER ratios in normal and myomatous human myometrium. East Afr Med J 1995; 72: 510-4
  17. Wu J, Cheng Y. Research on the relationship between estrogen receptor, progesterone receptor, cell proliferation associated antigen in uterine leiomyoma and nuclear body density of myoma, serum reproductive hormone oncentration. Chung-Hua FU Chan Ko Tsa Chih 1995; 30: 603-7
  18. Lee SH, Choi MH, Kim TW, Chung BC. Evaluation of endogenous steroids profile after administration of anabolic steroid. J Kor Chem Soc 1997; 41: 406-13
  19. Lee SH, Yang YJ, Kim TW, Paeng KJ, Chung BC. Urinary profiling of endogenous estrogens using GC/MS. J Kor Chem Soc 1997; 41: 186-97
  20. Pollow K, Sinnecker G, Boquai E, Pollow B. In vitro conversion of estradiol-$17{\ss}$ into estrone in normal human myometrium and leiomyoma. J Clin Chem Clin iochem 1978; 16:493-502
  21. Jasonni VM, Bonavia M, Lodi S, Preti S, Bulletti C, Flamigni C. Androstenedione metabolism in human uterine tissue: endometrium, myometrium and leiomyoma. J Steroid Biochem 1982; 17: 547-51 https://doi.org/10.1016/0022-4731(82)90014-0
  22. Yamamoto T, Fukuoka M, Fujimoto Y, Kitawaki J, Nakakosh M, Yoshihama M, Okada M. Inhibitory effect of a new androstenedione derivative, 14ahydroxy-4-androstene-3, 6, 17-trione (14a-OHAT) on aromatase activity of human uterine tumors. J Steroid Biochem 1990; 36: 517-20 https://doi.org/10.1016/0022-4731(90)90167-Q